Dorsey Wright & Associates Buys 201,041 Shares of Roivant Sciences Ltd. $ROIV

Dorsey Wright & Associates raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 53.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 577,147 shares of the company’s stock after buying an additional 201,041 shares during the quarter. Roivant Sciences accounts for about 2.0% of Dorsey Wright & Associates’ portfolio, making the stock its 13th largest position. Dorsey Wright & Associates’ holdings in Roivant Sciences were worth $15,987,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ROIV. California Public Employees Retirement System acquired a new position in shares of Roivant Sciences during the 1st quarter worth about $19,154,000. Bessemer Group Inc. boosted its stake in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after acquiring an additional 441 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Roivant Sciences during the 1st quarter worth approximately $3,957,000. Illinois Municipal Retirement Fund grew its holdings in Roivant Sciences by 96.6% during the first quarter. Illinois Municipal Retirement Fund now owns 119,384 shares of the company’s stock valued at $3,307,000 after purchasing an additional 58,649 shares during the period. Finally, Three Seasons Wealth LLC acquired a new position in Roivant Sciences during the first quarter valued at approximately $819,000. Institutional investors own 64.76% of the company’s stock.

Insider Buying and Selling at Roivant Sciences

In other news, Director Daniel Allen Gold sold 800,000 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the transaction, the director directly owned 13,701,546 shares of the company’s stock, valued at $473,388,414.30. This represents a 5.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Melissa B. Epperly sold 17,750 shares of Roivant Sciences stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the sale, the director directly owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,055,913 shares of company stock worth $68,567,633 over the last ninety days. Insiders own 10.80% of the company’s stock.

Roivant Sciences Trading Up 1.7%

ROIV opened at $34.51 on Friday. The stock’s fifty day simple moving average is $31.68 and its 200 day simple moving average is $28.17. Roivant Sciences Ltd. has a 1-year low of $10.90 and a 1-year high of $37.00. The stock has a market cap of $24.82 billion, a PE ratio of -57.52 and a beta of 1.11.

Analyst Upgrades and Downgrades

ROIV has been the topic of several analyst reports. Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Guggenheim lifted their target price on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Sanford C. Bernstein initiated coverage on Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 target price for the company. TD Cowen lifted their price objective on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Finally, HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $33.59.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.